The European Medicines Agency has launched a consultation on the lifecycle of personalised medicines and companion diagnostics.
The consultation will feed into the preparation of an EU guideline on the challenges of developing personalised medicines, the EMA said in a statement on 28 July.
Personalised medicines are treatments whose use is targeted based on a patient’s individual characteristics and genetic makeup. They rely on the use of a companion diagnostic that helps identify patients who are most likely to benefit from a specific treatment.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.